- $195.40m
- $159.17m
- $20.22m
- 23
- 10
- 89
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.27 | ||
| Price to Tang. Book | 6.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.66 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.32% | ||
| Return on Equity | -96.33% | ||
| Operating Margin | -95.94% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 21.76 | 23.76 | 26.5 | 18.69 | 20.22 | 24.35 | 30.8 | -8.65% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Directors
- Stephen Wills CHM (64)
- Sharon Malka CEO (49)
- Boaz Gur-Lavie CFO (47)
- Yaron Meyer EVP (42)
- Lior Rosenberg CTO (75)
- Ety Klinger OTH (59)
- David Fox DRC (63)
- Ofer Gonen DRC (48)
- Samuel Moed DRC (58)
- Assaf Segal DRC (49)
- Vickie Driver IND (67)
- Sharon Kochan IND (53)
- Nissim Mashiach IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 27th, 2000
- Public Since
- March 20th, 2014
- No. of Shareholders
- 1
- No. of Employees
- 111
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 10,807,726
- Address
- 42 Hayarkon Street, YAVNE, 8122745
- Web
- https://www.mediwound.com/
- Phone
- +972 89324010
- Contact
- Jeremy Feffer
- Auditors
- Somekh Chaikin
Upcoming Events for MDWD
Mediwound Ltd Annual Shareholders Meeting
Q2 2025 Mediwound Ltd Earnings Release
Similar to MDWD
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Mediwound share price?
As of Today at 21:59 UTC, shares in Mediwound are trading at $18.08. This share price information is delayed by 15 minutes.
How has the Mediwound share price performed this year?
Shares in Mediwound last closed at $18.08 and the price had moved by +2.38% over the past 365 days. In terms of relative price strength the Mediwound share price has underperformed the S&P500 Index by -5.5% over the past year.
What are the analyst and broker recommendations for Mediwound?
The overall consensus recommendation for Mediwound is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Mediwound dividend yield?
Mediwound does not currently pay a dividend.
Does Mediwound pay a dividend?
Mediwound does not currently pay a dividend.
When does Mediwound next pay dividends?
Mediwound does not currently pay a dividend.
How do I buy Mediwound shares?
To buy shares in Mediwound you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mediwound?
As of the previous close price of $18.08, shares in Mediwound had a market capitalisation of $195.40m.
Where are Mediwound shares listed?
Here are the trading details for Mediwound:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: MDWD
What kind of share is Mediwound?
Based on an overall assessment of its quality, value and momentum Mediwound is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mediwound share price forecast for 2025?
The analyst consensus target price for shares in Mediwound is $31.00. That is 71.46% above the last closing price of $18.08.
Analysts covering Mediwound currently have a consensus Earnings Per Share (EPS) forecast of -$2.84 for the next financial year.
Find out moreWhat is the trend in the Mediwound share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mediwound. Over the past six months, its share price has outperformed the S&P500 Index by +9.02%.
As of the last closing price of $18.08, shares in Mediwound were trading +2.22% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mediwound PE Ratio?
The Mediwound PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $18.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mediwound?
Mediwound's management team is headed by:
- Stephen Wills - CHM
- Sharon Malka - CEO
- Boaz Gur-Lavie - CFO
- Yaron Meyer - EVP
- Lior Rosenberg - CTO
- Ety Klinger - OTH
- David Fox - DRC
- Ofer Gonen - DRC
- Samuel Moed - DRC
- Assaf Segal - DRC
- Vickie Driver - IND
- Sharon Kochan - IND
- Nissim Mashiach - IND